Abstract
Obesity and the associated metabolic syndrome produce a complex set of alterations both systemically and locally in tissues that support cancer development and progression. In prostate cancer (PCa), the weight of evidence suggests that obesity is primarily associated with more aggressive disease and increased risk of biochemical failure following prostatectomy or radiation treatment. Inflammation processes and inflammation-associated signaling pathways are upregulated in the obese state, and both human and mouse studies support an important role for inflammation in obesity-driven PCa progression. Inflammation signaling pathways along with other signaling pathways (e.g., growth factor signaling pathways) altered in the obese state represent promising targets for both lifestyle and pharmacologic interventions to prevent or control PCa progression.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497
Grassi G, Seravalle G, Scopelliti F, Dell’Oro R, Fattori L, Quarti-Trevano F et al (2010) Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 18:92–98
Gottschling-Zeller H, Birgel M, Scriba D, Blum WF, Hauner H (1999) Depot-specific release of leptin from subcutaneous and omental adipocytes in suspension culture: effect of tumor necrosis factor-alpha and transforming growth factor-beta1. Eur J Endocrinol 141:436–442
Ford ES, Li C, Zhao G (2010) Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2:180–193
Hursting SD, Berger NA (2010) Energy balance, host-related factors, and cancer progression. J Clin Oncol 28:4058–4065
Carter JC, Church FC (2009) Obesity and breast cancer: the roles of peroxisome proliferator-Âactivated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res 2009:345320
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX et al (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26:968–976
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638
Stocks T, Borena W, Strohmaier S, Bjorge T, Manjer J, Engeland A et al (2010) Cohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol 39:660–667
Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H et al (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551
Stephenson RA, Stanford JL (1997) Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 15:331–335
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Nomura AM (2001) Body size and prostate cancer. Epidemiol Rev 23:126–131
Porter MP, Stanford JL (2005) Obesity and the risk of prostate cancer. Prostate 62:316–321
Flavin R, Zadra G, Loda M (2011) Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223:283–294
Allott EH, Masko EM, Freedland SJ (2012) Obesity and prostate cancer: weighing the evidence. Eur Urol. 2012. pii:S0302–2838(12)01344-9. doi:10.1016/j.eururo.2012.11.013
Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT et al (2000) Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer 89:259–264
Giovannucci E, Rimm EB, Stampfer M, Colditz GA, Willett W (1997) Height, body weight and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 6(8):557–563
Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T et al (1983) Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70:687–692
Mettlin C, Selenskas S, Natarajan N, Huben R (1989) Beta-carotene and animal fats and their relationship to prostate cancer risk. A case–control study. Cancer 64:605–612
Strom SS, Yamamura Y, Forman MR, Pettaway CA, Barrera SL, DiGiovanni J (2008) Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer 122:2581–2585
Kondo Y, Homma Y, Aso Y, Kakizoe T (1994) Promotional effect of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. Cancer Res 54:6129–6132
Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA et al (2010) Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) 3:279–289
Hsu IR, Kim SP, Kabir M, Bergman RN (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:s867–s871
Zhou JR, Blackburn GL, Walker WA (2007) Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 86:s817–s819
Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13:1646–1650
White MF, Kahn CR (1994) The insulin signaling system. J Biol Chem 269:1–4
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al (2007) Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99:1793–1800
Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406–1418
Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099–1106
Burton AJ, Tilling KM, Holly JM, Hamdy FC, Rowlands MA, Donovan JL et al (2010) Metabolic imbalance and prostate cancer progression. Int J Mol Epidemiol Genet 1:248–271
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al (2008) Prediagnostic body-Âmass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039–1047
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928
Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary Âprostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942–2950
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E et al (2009) Insulin receptor expression by human prostate cancers. Prostate 69:33–40
Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 114:71–83
Platz EA, Giovannucci E (2004) The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92:237–253
Hsing AW, Reichardt JK, Stanczyk FZ (2002) Hormones and prostate cancer: current perspectives and future directions. Prostate 52:213–235
Gapstur SM, Kopp P, Gann PH, Chiu BC, Colangelo LA, Liu K (2007) Changes in BMI modulate age-associated changes in sex hormone binding globulin and total testosterone, but not bioavailable testosterone in young adult men: the CARDIA Male Hormone Study. Int J Obes (Lond) 31:685–691
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850
Goldstein BJ (2003) Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 4(suppl 6):S3–S10
Littman AJ, White E, Kristal AR (2007) Anthropometrics and prostate cancer risk. Am J Epidemiol 165:1271–1279
Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86:s843–s857
Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772–783
Baillargeon J, Rose DP (2006) Obesity, adipokines, and prostate cancer (review). Int J Oncol 28:737–745
Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301–316
Mistry T, Digby JE, Desai KM, Randeva HS (2007) Obesity and prostate cancer: a role for adipokines. Eur Urol 52:46–53
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295
Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ et al (2001) Leptin and prostate cancer. Prostate 46:62–67
Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P et al (2005) Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 174:1266–1270
Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93:783–789
Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T et al (2003) Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 12:309–315
Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS (1998) Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 76:25–28
Saglam K, Aydur E, Yilmaz M, Goktas S (2003) Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169:1308–1311
Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H et al (2003) Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 12:474–475
Ribeiro R, Lopes C, Medeiros R (2004) Leptin and prostate: implications for cancer prevention—overview of genetics and molecular interactions. Eur J Cancer Prev 13:359–368
Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188:560–565
Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC et al (1998) Biological action of leptin as an angiogenic factor. Science 281:1683–1686
Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N (2008) Leptin signaling in breast cancer: an overview. J Cell Biochem 105:956–964
Hoda MR, Popken G (2008) Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int 102:383–388
Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451
Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W et al (2012) Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) 5:1260–1272
Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777–794
Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL et al (2011) The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study. Breast Cancer Res Treat 129:175–184
Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117:2362–2368
Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409
Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523–527
Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED (2012) Differential expression of VEGF ligands and receptors in prostate cancer. Prostate. doi:10.1002/pros.22596
Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K et al (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55:4140–4145
Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP et al (1997) Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329–2333
George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N et al (2004) Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 63:327–332
El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R et al (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127:572–579
Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ (2004) Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18:155–160
Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ et al (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61:2533–2536
George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-Ârefractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932–1936
Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61:2736–2743
Turner K, Jones A (2000) Vascular endothelial growth factor in prostate cancer. Urology 56:183
Jackson MW, Bentel JM, Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157:2323–2328
Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K (1996) Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74:910–916
Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z et al (2005) Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 65:10921–10929
Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N (1998) Neutralizing anti-Âvascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1–10
Iwaki T, Urano T, Umemura K (2012) PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157:291–298
Skurk T, Hauner H (2004) Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 28:1357–1364
Muldowney JA III, Chen Q, Blakemore DL, Vaughan DE (2012) Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study. Angiology 63:429–434
Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L et al (1995) Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res 7:131–138
Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J (2001) Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8:463–470
Sfanos KS, De Marzo AM (2012) Prostate cancer and inflammation: the evidence. Histopathology 60:199–215
Gueron G, De Siervi A, Vazquez E (2012) Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15:213–221
Koul HK, Kumar B, Koul S, Deb AA, Hwa JS, Maroni P et al (2010) The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today (Barc) 46:929–943
Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97
Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2:384–396
Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90:2312–2316
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H et al (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702–2706
Knupfer H, Preiss R (2008) sIL-6R: more than an agonist? Immunol Cell Biol 86:87–91
Akimoto S, Okumura A, Fuse H (1998) Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 45:183–189
Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127–133
Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF et al (2009) Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 182:1621–1627
Akira S (1997) IL-6-regulated transcription factors. Int J Biochem Cell Biol 29:1401–1418
Rose-John S (2001) Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol 495:145–151
Lin DL, Whitney MC, Yao Z, Keller ET (2001) Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7:1773–1781
Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60:2132–2135
Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H et al (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640–4645
Culig Z (2003) Role of the androgen receptor axis in prostate cancer. Urology 62:21–26
Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565–573
van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397–408
Robinson SC, Coussens LM (2005) Soluble mediators of inflammation during tumor development. Adv Cancer Res 93:159–187
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78
Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4:1743–1748
Huerta-Yepez S, Vega M, Garban H, Bonavida B (2006) Involvement of the TNF-alpha autocrine-Âparacrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol 120:297–309
Ohshima H, Tazawa H, Sylla BS, Sawa T (2005) Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 591:110–122
Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322
Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN (2006) Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38:1654–1661
Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1–20
Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG (2001) Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61:2720–2726
Munoz-Espada AC, Watkins BA (2006) Cyanidin attenuates PGE2 production and cyclooxygenase-Â2 expression in LNCaP human prostate cancer cells. J Nutr Biochem 17:589–596
Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250–3256
Hensley PJ, Kyprianou N (2012) Modeling prostate cancer in mice: limitations and Âopportunities. J Androl 33:133–144
Wang F (2011) Modeling human prostate cancer in genetically engineered mice. Prog Mol Biol Transl Sci 100:1–49
Ahmad I, Sansom OJ, Leung HY (2008) Advances in mouse models of prostate cancer. Expert Rev Mol Med 10:e16
Szymanska H (2007) [Genetically engineered mice: mouse models for cancer research]. Postepy Hig Med Dosw (Online) 61:639–645
Huffman DM, Johnson MS, Watts A, Elgavish A, Eltoum IA, Nagy TR (2007) Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake. Cancer Res 67:417–424
Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP et al (2010) A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol 177:3180–3191
Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L et al (2011) Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila) 4:2002–2014
Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M et al (2008) Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res 68:3066–3073
Ribeiro AM, Andrade S, Pinho F, Monteiro JD, Costa M, Lopes C et al (2010) Prostate cancer cell proliferation and angiogenesis in different obese mice models. Int J Exp Pathol 91:374–386
Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL et al (2009) White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 69:5259–5266
Lamarre NS, Ruggieri MR Sr, Braverman AS, Gerstein MI, Mydlo JH (2007) Effect of obese and lean Zucker rat sera on human and rat prostate cancer cells: implications in obesity-Ârelated prostate tumor biology. Urology 69:191–195
Price RS, Cavazos DA, De Angel RE, Hursting SD, de Graffenried LA (2012) Obesity-Ârelated systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 15:135–143
National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 6(suppl 2):51S–209S
Vainio H, Kaaks R, Bianchini F (2002) Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 11(suppl 2):S94–S100
Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB et al (1997) Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 8:229–238
Hartman TJ, Albanes D, Rautalahti M, Tangrea JA, Virtamo J, Stolzenberg R et al (1998) Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland). Cancer Causes Control 9:11–18
Oliveria SA, Lee IM (1997) Is exercise beneficial in the prevention of prostate cancer? Sports Med 23:271–278
Kelley DE, Goodpaster BH (1999) Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exerc 31:S619–S623
Chang S, Wu X, Yu H, Spitz MR (2002) Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev 11:758–766
Kraemer RR, Chu H, Castracane VD (2002) Leptin and exercise. Exp Biol Med (Maywood) 227:701–708
Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, Pories WJ et al (2003) Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 284:E741–E747
Nindl BC, Kraemer WJ, Arciero PJ, Samatallee N, Leone CD, Mayo MF et al (2002) Leptin concentrations experience a delayed reduction after resistance exercise in men. Med Sci Sports Exerc 34:608–613
Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA (2003) A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56:201–206
Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ (2004) Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 96:450–454
Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ et al (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174:1065–1069; discussion 1069–1070
Ribaric S (2012) Diet and aging. Oxid Med Cell Longev 2012:741468
Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA et al (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3:e2264
Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N et al (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8:157–168
Li G, Rivas P, Bedolla R, Thapa D, Reddick RL, Ghosh R et al (2012) Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila) 6(1):27–39
Kwon KH, Barve A, Yu S, Huang MT, Kong AN (2007) Cancer chemoprevention by Âphytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol Sin 28:1409–1421
Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H (2004) Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64:8715–8722
Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 29:1990–1991
Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study. Cancer Causes Control 20:1617–1622
Zadra G, Priolo C, Patnaik A, Loda M (2010) New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 16:3322–3328
Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1:369–375
Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576–3586
Acknowledgments
Achinto Saha is supported by a Cancer Prevention Research Institute of Texas postdoctoral fellowship award RP101501 from the State of Texas.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Blando, J., Saha, A., Kiguchi, K., DiGiovanni, J. (2013). Obesity, Inflammation, and Prostate Cancer. In: Dannenberg, A., Berger, N. (eds) Obesity, Inflammation and Cancer. Energy Balance and Cancer, vol 7. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6819-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6819-6_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6818-9
Online ISBN: 978-1-4614-6819-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)